Precede Biosciences
Boston
About Precede Biosciences
Precede Biosciences is a biotechnology company that provides a blood-based approach to reveal disease-defining transcriptional biology. The company aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. It provides a genome-wide platform that simultaneously explores the dynamic, feature-rich space of gene promoters, gene enhancers, and the DNA methylome from a single milliliter (1 mL) of plasma. It is actively partnering with drug developers to accelerate the development of precision medicines by identifying the biology associated with response and resistance to treatment and by identifying targets mechanistically linked to disease biology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $140.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2026)
- Website: precede.bio
- Phone: (617) 356-1457
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/precede-biosciences-11415 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.